Top Big Pharma Stocks: Our 5 Best Stock Picks for July 2026
Five big pharma stocks are ranked in a countdown, comparing specialty franchises, profitability, valuation, growth and earnings consistency for July 2026.
Big pharma remains one of healthcare’s most durable investment themes because it pairs recurring demand with the possibility of product-driven growth. Aging populations, chronic-disease prevalence and continued adoption of biologics and specialty medicines support the sector’s long runway, while established drug franchises can generate the cash needed to fund research, acquisitions and shareholder returns. The central question for investors in July 2026 is not simply which companies sell the most medicines. It is which operators can convert established scale into durable innovation while managing patent-expiry, pricing and biosimilar risks.
The value chain matters. Legacy blockbusters provide funding, newer specialty franchises drive current growth, and pipeline assets help offset future exclusivity losses. Recent results illustrate that transition: AbbVie reported that its growth platform represented 93% of total revenue in 2025, with Skyrizi and Rinvoq posting strong double-digit growth. Pfizer continues to manage a broad portfolio anchored by products including Eliquis, while Merck’s Keytruda and Winrevair, Johnson & Johnson’s innovative-medicine and MedTech operations, and Amgen’s established biologics and newer launches show how the sector is moving beyond traditional primary-care drugs.
This ranking emphasizes investment quality rather than short-term price momentum. We weigh profitability, growth, valuation, earnings execution, balance-sheet considerations and analyst sentiment, then present the results in countdown order from #5 to #1. The lower-ranked names can still offer useful exposure to defensive healthcare cash flows or recovery potential, but the final selections receive the strongest overall consideration within this five-stock big pharma universe.
Our screen is limited to U.S.-listed companies with market capitalizations above $500 million, then ranks candidates by investment quality using composite metrics and primary-source financial data. The review considers each company’s operating margins, return measures, revenue and earnings growth, valuation, recent earnings surprises and analyst consensus. This is a countdown, so the best pick is intentionally reserved for #1 at the end. The grades are not standalone recommendations; they are a structured way to compare businesses with different mixes of growth, profitability, portfolio concentration and balance-sheet risk.
What they do. The company discovers, develops, manufactures and delivers human therapeutics worldwide. Its portfolio spans inflammation products such as Enbrel and Otezla, bone-health medicines including Prolia, XGEVA and EVENITY, cardiovascular therapy Repatha, and specialty oncology and rare-disease products including BLINCYTO, KYPROLIS, TEPEZZA and KRYSTEXXA. Distribution through wholesalers to physicians, hospitals, dialysis centers and pharmacies gives Amgen a broad commercial reach, while collaborations with AstraZeneca, UCB, Kyowa Kirin and BeiGene extend its development and commercialization network.
Why it fits. Amgen fits the big pharma theme through a diversified biologics and specialty-medicine platform rather than dependence on a single therapeutic area. Products addressing osteoporosis, cardiovascular risk, autoimmune disease, cancer and rare conditions give investors exposure to several of the sector’s key growth categories. The company’s established franchises also provide a base for newer launches and partnered programs, a useful model for navigating patent pressure and changing treatment standards.
Numbers that matter. Amgen produced a 71.4% gross margin, a 33.8% operating margin and a 20.96% net margin. Revenue grew 5.8% year over year, while earnings growth was 4.4%; trailing EPS was $14.19 and next-year EPS is estimated at $23.44. Core valuation data show a trailing P/E of 27.3178 and a forward P/E of 17.6991. The combination of positive growth and a lower forward multiple supports the quality case, although the composite balance-sheet metrics are a clear weakness.
Recent momentum. Amgen beat the EPS estimate in each of the seven reported quarters in the available beat-rate record. In the latest reported quarter, EPS was $5.15 versus an estimate of $4.77, an 8.0% surprise. Analyst sentiment is more measured: five analysts rate the shares Buy, 14 rate them Hold and one rates them Sell, producing a 3.625 consensus score and an average target of $357.03.
Market cap: $142.0B · Quality grade: B · Analyst consensus: Hold (avg target $28.75)
What they do. The company discovers, develops, manufactures, markets and distributes biopharmaceutical products through its Biopharma, PC1 and Pfizer Ignite segments. Its portfolio includes cardiovascular and metabolic products under Eliquis, vaccines such as Prevnar and Abrysvo, COVID-19 treatment Paxlovid, inflammation and immunology medicines, rare-disease products under the Vyndaqel family, and a broad oncology franchise spanning Ibrance, Xtandi, Padcev, Adcetris and other therapies. This breadth gives Pfizer a global commercial infrastructure across primary care, specialty medicine, vaccines, oncology and biosimilars.
Why it fits. Pfizer represents the scale and portfolio reshaping central to the big pharma thesis. Eliquis and the vaccine franchise contribute major commercial reach, while oncology, rare disease, immunology and biosimilars provide avenues to rebalance the portfolio as product cycles change. The company’s mix of branded therapies, vaccines, sterile injectables and biosimilars also gives it multiple routes to defend revenue rather than relying on one therapeutic category.
Numbers that matter. Pfizer’s gross margin was 74.8%, with a 31.62% operating margin and an 11.83% net margin. Revenue increased 5.4% year over year, but earnings declined 10.1%; trailing EPS was $1.31, compared with a next-year EPS estimate of $2.8318. Core valuation data list a trailing P/E of 19.1985 and a forward P/E of 8.6207. That forward valuation is relatively restrained, but the earnings decline explains why the stock ranks below companies with cleaner current profitability and growth profiles.
Recent momentum. Pfizer has beaten EPS estimates in all seven reported quarters in the available record. The latest reported quarter delivered EPS of $0.75 against an estimate of $0.72, a 4.2% surprise. Analysts remain cautious but not uniformly negative: two rate the shares Buy and 15 rate them Hold, while the consensus score is 3.56 and the average target is $28.75.
What they do. The company operates through Innovative Medicine and MedTech. Innovative Medicine covers oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases and cardiovascular and metabolic conditions, while MedTech supplies products for surgery, orthopedics, cardiovascular care and vision, including joint reconstruction, robotic and digital technologies, contact lenses and intraocular lenses. The combination gives Johnson & Johnson a broader healthcare revenue model than a pure-play drugmaker, with prescription medicines complemented by procedure-linked medical technology.
Why it fits. Johnson & Johnson fits the theme through the scale of its Innovative Medicine franchise and the diversification of MedTech. Its exposure to oncology and immunology aligns with major specialty-drug trends, while surgical, orthopedic, cardiovascular and vision products broaden the company’s participation in healthcare demand. That mix can make the business less dependent on any single drug cycle, although it also means investors must evaluate both pharmaceutical innovation and device execution.
Numbers that matter. Johnson & Johnson generated a 68.1% gross margin, a 29.19% operating margin and a 21.48% net margin. Revenue grew 6.6% year over year, while earnings declined 0.9%; trailing EPS was $8.58 and next-year EPS is estimated at $12.8322. Its core trailing P/E of 30.9476 and forward P/E of 22.8833 are higher than Pfizer’s, placing more emphasis on the company’s profitability and diversification. Return on equity was 25.74% and return on assets was 8.6%.
Recent momentum. The company has beaten EPS estimates in six of the seven reported quarters in the available record. In the latest report, EPS came in at $2.90 versus an estimate of $2.84, a 2.1% surprise. The analyst breakdown includes four Buy ratings and 13 Hold ratings, with no Sell count provided; the consensus score is 3.75 and the average target is $270.59.
Pick #2Premium members only
Premium members see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
This monthly screen begins with U.S.-listed healthcare companies whose market capitalization exceeds $500 million, then narrows the universe to businesses with meaningful pharmaceutical or biopharmaceutical operations. The ranking is based on investment quality, using a combination of composite grade, profitability, return on equity and assets, revenue and earnings growth, trailing and forward valuation, earnings-surprise consistency, analyst consensus and balance-sheet considerations. It is not a forecast of near-term share performance. The article is refreshed monthly so the comparison can incorporate updated financial results, estimates, analyst views and market-cap data while preserving the countdown format.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
